|
Chugai Pharmaceutical Co., Ltd.,an R&D-oriented pharmaceutical company Chugai is working to satisfy unmet medical needs by developing innovative new drugs using its unique technology and science, announced that the results of a collaborative study conducted under the comprehensive collaboration agreement with the Immunology Frontier Research Center (IFReC) at Department of Haematology and Oncology, Graduate School of Medicine, Osaka University, have been published online in the scientific journal Blood. Blood is the journal of the American Society of Haematology and is among the most authoritative journals in the field of haematology, publishing important and up-to-date research findings spanning from basic to clinical studies on blood disorders.
This study identified, for the first time, a subgroup of patients with immune thrombocytopenia (ITP) in whom complement activation is involved, and it revealed a potential simple test that could be readily used in routine clinical practice to detect such cases.
This study demonstrated the following:
- The pathophysiology of immune thrombocytopenia (ITP) varies among patients, and the causes and mechanisms of platelet destruction have not been fully elucidated; this study identified three distinct mechanisms of platelet destruction.
- The findings suggest the possibility of a simple, clinically feasible method to identify patients for whom complement activation inhibitors are likely to be effective.
|